Results 51 to 60 of about 19,799 (257)

Percutaneous transluminal coronary angioplasty in the right ventricle myocardial infarction treatment [PDF]

open access: yesVojnosanitetski Pregled, 2005
Background/Aim. To present the results of percutaneous transluminal coronary angioplasty (PTCA) in the treatment of the patients with acute right ventricle myocardial infarction (ARVMI), with adjuvant analyses of the obtained results in the period of ...
Rafajlovski Saša I.   +3 more
doaj   +1 more source

Artificial Host‐Guest Recognition Directs Glycometabolically Engineered Macrophages to Tumors

open access: yesAdvanced Science, EarlyView.
Glycoengineered supramolecular macrophages (GSAR‐M) are developed using glycometabolic labeling for bioorthogonal host‐guest tumor targeting. This engineering approach unexpectedly enhances macrophage migration, phagocytosis, and pseudopodia formation. Consequently, GSAR‐M demonstrate robust tumor‐targeting specificity, effectively arrest tumor growth,
Zhiqing Yang   +8 more
wiley   +1 more source

Bernard–Soulier syndrome caused by two novel heterozygous GP1BA gene mutations: a case report and literature review

open access: yesHematology
Background: Bernard–Soulier syndrome (BSS) is a rare inherited macrothrombocytopenia, usually autosomal recessive, which is characterized by prolonged bleeding, thrombocytopenia, and abnormally large platelets.Methods: For more than 6 years, we ...
Senlin Zhang   +7 more
doaj   +1 more source

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy

open access: yesAdvanced Science, EarlyView.
This study shows that a PARP inhibitor combined with anlotinib, administered as bridging therapy, preconditions the tumor microenvironment to enhance the infiltration and antitumor activity of subsequently infused CAR‐T cells across preclinical ovarian cancer models, supporting bridging therapy as a promising strategy to address limited CAR‐T cell ...
Huayi Li   +20 more
wiley   +1 more source

Analysis of Platelet Membrane Glycoproteins in Myeloproliferative Disorders

open access: yesBlood & Vessel, 1979
The platelet membrane glycoproteins (GP) of myeloproliperetion disorders(12 cases) were analyzed by SDS PAGE. In GP I peak there was no difference between normal and this disorders in the 125I incorporation rate but the percentage of GP I to all PAS stained peaks was reduced in chronic myelogenous leukemia (CML) but increased in primary thrombo ...
FUJIMURA, Kingo   +2 more
openaire   +2 more sources

Rewriting Tumor Immunity With Bacterial Membrane Vesicles: A Versatile and Potent Therapeutic Strategy

open access: yesAdvanced NanoBiomed Research, EarlyView.
Bacterial membrane vesicles (BMVs) emerge as promising platforms for cancer immunotherapy owing to their intrinsic adjuvant properties and tunable cargo delivery capabilities. Their ability to modulate the tumor microenvironment, enhance antitumor immune responses, and support personalized therapeutic strategies highlights their growing potential as ...
Md Sifat Rahi   +6 more
wiley   +1 more source

Noncanonical effects of vasopressin in angiogenesis

open access: yesВавиловский журнал генетики и селекции, 2019
The molecular action of vasopressin depends on the localization of hormonal receptors. The basic physiological effects of vasopressin are manifested in the blood vasculature, renal inner medulla and brain.
I. I. Khegay
doaj   +1 more source

Biomimetic Nanoparticle Delivering Colchicine to Target Endothelial Inflammation for Atherosclerosis Treatment

open access: yesAdvanced NanoBiomed Research, EarlyView.
Platelet membrane‐coated layered double hydroxide nanoparticles were engineered to target inflamed endothelium at early‐stage atherosclerosis and enhance therapeutic efficacy. The biomimetic platform improves stability, immune escape, and inflamed vascular cell targeting, resulting in reduced oxidative stress and downregulated adhesion molecules.
Xiuwen Zhang   +4 more
wiley   +1 more source

Levonorgestrel-releasing intrauterine system for treatment of heavy menstrual bleeding in adolescents with Glanzmann’s Thrombasthenia: illustrated case series

open access: yesBMC Women's Health, 2018
Background Glanzmann’s Thrombasthenia (GT) is an inherited genetic disorder caused by defects in the platelet membrane glycoproteins IIb/IIIA, and is associated with heavy menstrual bleeding (HMB).
Meiqiu Lu, Xin Yang
doaj   +1 more source

Home - About - Disclaimer - Privacy